U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug

U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
@ Copyright :
Kim Kyung Hoon(Reuters)
Text size Aa Aa

By Jonathan Stempel

(Reuters) - A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million (£119.91 million) for infringing a patent related to a Baxalta haemophilia treatment, court records made public on Tuesday show.

Jurors in the federal court in Wilmington, Delaware, reached their verdict on the seventh day of a trial, after rejecting Baxalta's argument that the June 2016 patent on the treatment, Adynovate, was invalid.

Bayer said the infringement arose from Baxalta's exclusive licence agreement with Nektar Therapeutics, a San Francisco-based company that had done research with Bayer and knew about the patent, including through litigation in Germany.

The award covered the period from June 14, 2016 to Nov. 30, 2018. Jurors applied a royalty rate of 17.78 percent to a royalty base of $872.84 million to arrive at the damages award.

Bayer is based in Leverkusen, Germany, with U.S. offices in Whippany, New Jersey.

Baxalta was based in Illinois before Shire Plc acquired the company in 2016. Takeda completed an acquisition of Shire for roughly $59 billion last month.

Takeda did not immediately respond to requests for comment.

Bayer said it was pleased with the verdict, "which confirms the strength of Bayer's innovation in haemophilia treatment."

Haemophilia is a mostly inherited disorder where blood fails to clot properly. It can result in prolonged bleeding after an injury.

Shire's sales of Adynovate and other haemophilia treatments totalled $2.23 billion in the nine months ending Sept. 30, 2018, including $1.15 billion in the United States.

The case is Bayer Healthcare LLC v Baxalta Inc et al, U.S. District Court, District of Delaware, No. 16-01122.

(Reporting by Jonathan Stempel in New York; editing by Bill Berkrot)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.